Patents by Inventor Matthew Cooper

Matthew Cooper has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20240122596
    Abstract: Disclosed are techniques for stapler reload detection and identification. A manipulator is configured to have an instrument mounted thereto. The instrument includes an end effector configured to receive a replaceable stapler cartridge. An actuator is drivingly coupled with the pusher member. A control unit is configured to control operation of the actuator to move the pusher member from a first position toward a second position; determine a distance that the pusher member moves from the first position toward the second position before a force limit for the actuator is exceeded; and determine, based on the distance that the pusher member moves, an operational status of the instrument relating to the replaceable stapler cartridge.
    Type: Application
    Filed: December 26, 2023
    Publication date: April 18, 2024
    Inventors: William BURBANK, Matthew A. WIXEY, Nicholas RAGOSTA, David W. WEIR, Emily COOPER, Melody WU
  • Publication number: 20240121337
    Abstract: One example method of operation may include identifying a call originated from a caller entity destined for a called entity at a call content server, identifying a called number associated with the called entity and a caller number associated with the caller entity, comparing a telephone number prefix associated with the called number with a number of enhanced call content data elements to identify a match, selecting one or more of the enhanced call content data elements to pair with the called number based on the match, and forwarding the selected enhanced call content data elements to the called entity.
    Type: Application
    Filed: December 17, 2023
    Publication date: April 11, 2024
    Applicant: FIRST ORION CORP.
    Inventors: Brandon Wayne Murphy, Robert Collin Seely, Aaron Christopher Jacobi, Benjamin Michael Lavigne, Mark Bradley McHenry, John Cooper Gillespie, Matthew Jack Beckham, Kristen Chipolla Sanchez, Lyndsay Michelle Norcross, Jay Todd Callaway
  • Patent number: 11950078
    Abstract: Methods for dialogue enhancing audio content, comprising providing a first audio signal presentation of the audio components, providing a second audio signal presentation, receiving a set of dialogue estimation parameters configured to enable estimation of dialogue components from the first audio signal presentation, applying said set of dialogue estimation parameters to said first audio signal presentation, to form a dialogue presentation of the dialogue components; and combining the dialogue presentation with said second audio signal presentation to form a dialogue enhanced audio signal presentation for reproduction on the second audio reproduction system, wherein at least one of said first and second audio signal presentation is a binaural audio signal presentation.
    Type: Grant
    Filed: April 28, 2023
    Date of Patent: April 2, 2024
    Assignees: Dolby Laboratories Licensing Corporation, DOLBY INTERNATIONAL AB
    Inventors: Leif Jonas Samuelsson, Dirk Jeroen Breebaart, David Matthew Cooper, Jeroen Koppens
  • Publication number: 20240105186
    Abstract: A method for encoding an input audio stream including the steps of obtaining a first playback stream presentation of the input audio stream intended for reproduction on a first audio reproduction system, obtaining a second playback stream presentation of the input audio stream intended for reproduction on a second audio reproduction system, determining a set of transform parameters suitable for transforming an intermediate playback stream presentation to an approximation of the second playback stream presentation, wherein the transform parameters are determined by minimization of a measure of a difference between the approximation of the second playback stream presentation and the second playback stream presentation, and encoding the first playback stream presentation and the set of transform parameters for transmission to a decoder.
    Type: Application
    Filed: October 16, 2023
    Publication date: March 28, 2024
    Applicants: DOLBY LABORATORIES LICENSING CORPORATION, DOLBY INTERNATIONAL AB
    Inventors: Dirk Jeroen Breebaart, David Matthew Cooper, Leif Jonas Samuelsson, Jeroen Koppens, Rhonda J. Wilson, Heiko Purnhagen, Alexander Stahlmann
  • Patent number: 11933129
    Abstract: A drilling and production system is provided. In one embodiment, such a system has a plurality of functions that are effectuated at least predominately without hydraulic fluid. The system can be a drilling system having a rig and a subsea stack for performing various drilling functions, in which a majority of the drilling functions are effected electrically without hydraulic control fluid. In another embodiment, the rig is coupled to a subsea wellhead assembly but is not connected so as to provide hydraulic control fluid from the rig to the subsea wellhead assembly to enable drilling functions of the subsea wellhead assembly. Additional systems, devices, and methods are also disclosed.
    Type: Grant
    Filed: June 23, 2023
    Date of Patent: March 19, 2024
    Assignee: SCHLUMBERGER TECHNOLOGY CORPORATION
    Inventors: Vikas Rakhunde, Nathan Cooper, Justin Blair, Michael W. Berckenhoff, Michael Mancuso, Matthew Givens
  • Patent number: 11926600
    Abstract: The present invention relates to sulfonylureas and sulfonylthioureas comprising a monocyclic imidazolyl group of formula (I): wherein Q is selected from O or S, R1 is an imidazolyl group, wherein the imidazolyl group is unsubstituted or substituted with one or more monovalent substituents, and R2 is a cyclic group substituted at the ?-position, wherein R2 may optionally be further substituted. The present invention further relates to salts, solvates and prodrugs of such compounds, to pharmaceutical compositions comprising such compounds, and to the use of such compounds in the treatment and prevention of medical disorders and diseases, most especially by the inhibition of NLRP3.
    Type: Grant
    Filed: August 15, 2018
    Date of Patent: March 12, 2024
    Assignee: INFLAZOME LIMITED
    Inventors: Matthew Cooper, David Miller, Angus MacLeod, Stephen Thom, Stephen St-Gallay, Jonathan Shannon
  • Publication number: 20240075141
    Abstract: Among the various aspects of the present disclosure is the provision of improved chimeric receptor constructs for NK cells, NK cells containing such receptors and methods of making and using same.
    Type: Application
    Filed: March 17, 2023
    Publication date: March 7, 2024
    Inventors: You ZHOU, Matthew COOPER, Elizabeth SCHRAMM
  • Patent number: 11924373
    Abstract: One example method of operation may include identifying a call originated from a caller entity destined for a called entity at a call content server, identifying a called number associated with the called entity and a caller number associated with the caller entity, comparing a telephone number prefix associated with the called number with a number of enhanced call content data elements to identify a match, selecting one or more of the enhanced call content data elements to pair with the called number based on the match, and forwarding the selected enhanced call content data elements to the called entity.
    Type: Grant
    Filed: November 19, 2021
    Date of Patent: March 5, 2024
    Assignee: FIRST ORION CORP.
    Inventors: Brandon Wayne Murphy, Robert Collin Seely, Aaron Christopher Jacobi, Benjamin Michael Lavigne, Mark Bradley McHenry, John Cooper Gillespie, Matthew Jack Beckham, Kristen Chipolla Sanchez, Lyndsay Michelle Norcross, Jay Todd Callaway
  • Patent number: 11905252
    Abstract: The present invention relates to sulfonylureas and sulfonylthioureas of formula (I) comprising a 5-membered heteroaryl ring attached to the sulfonyl group, wherein the heteroaryl ring is di-substituted at the 3- and 4-positions relative to the point of attachment of the sulfonyl group, and wherein the group attached to the terminal nitrogen atom of the urea group is either a 1,2,3,5,6,7-hexahydro-s-indacen-4-yl group substituted at the 8-position, or a heteroaryl group substituted at the alpha and alpha? positions. The present invention further relates to salts, solvates and prodrugs of such compounds, to pharmaceutical compositions comprising such compounds, and to the use of such compounds in the treatment and prevention of medical disorders and diseases, most especially by NLRP3 inhibition.
    Type: Grant
    Filed: March 1, 2019
    Date of Patent: February 20, 2024
    Assignee: INFLAZOME LIMITED
    Inventors: Matthew Cooper, David Miller, Angus Macleod, Jonathan Shannon
  • Publication number: 20240033357
    Abstract: The disclosure relates to chimeric antigen receptors and immune effector cells bearing chimeric antigen receptors (CARs). Disclosed herein are improved CARs that are able to recruit Lck and/or and PLC? without the need to express CD2, thereby providing efficient CAR function without the risk of CD2-induced fratricide; optionally, the CARs also comprise CD132. Further disclosed herein are improved CARs specific for CD2. Further disclosed herein are improved immune effector cells bearing such improved CARs, therapeutic compositions comprising such improved immune effector cells, and methods for treating cancer using such improved immune effector cells and/or therapeutic compositions.
    Type: Application
    Filed: October 10, 2023
    Publication date: February 1, 2024
    Inventors: You W. ZHOU, Matthew COOPER, James P. WHITE
  • Patent number: 11884645
    Abstract: The present invention relates to compounds of formula (1): wherein Q is selected from O or S; R1 is a 5-membered nitrogen-containing heteroaryl group substituted with R6 and optionally further substituted; R2 is an alpha, alpha?-substituted cyclic group which may optionally be further substituted; R3 and R4 are each independently hydrogen, halogen, —OH, —NH2, —CN, —R5, —OR5, —NHR5 or —N(R5)2; or R3 and R4 together with the carbon atom to which they are attached may form a 3 to 7 membered saturated or unsaturated, optionally substituted cyclic group; R5 is independently an optionally substituted C1-C4 alkyl group; and R6 is any group comprising a nitrogen atom. The present invention further relates to salts, solvates and prodrugs of such compounds, to pharmaceutical compositions comprising such compounds, and to the use of such compounds in the treatment and prevention of medical disorders and diseases, most especially by the inhibition of NLRP3.
    Type: Grant
    Filed: March 1, 2019
    Date of Patent: January 30, 2024
    Assignee: INFLAZOME LIMITED
    Inventors: David Miller, Jimmy Van Wiltenburg, Matthew Cooper
  • Patent number: 11872626
    Abstract: Techniques for joining nodes and subcomponents are presented herein. An apparatus in accordance with an aspect of the present disclosure comprises a 3-D printed first part having an interconnect co-printed with the first part such that the interconnect of the first part can float within the first part, and a 3-D printed second part having an interconnect co-printed with the second part such that the interconnect of the second part can float within the second part, wherein the interconnects of the first and second parts are configured to form a connection between the first and second parts.
    Type: Grant
    Filed: November 5, 2021
    Date of Patent: January 16, 2024
    Assignee: DIVERGENT TECHNOLOGIES, INC.
    Inventors: Samuel Noah Miller, Matthew Cooper Keller, Eric Paul Monteith, Thomas Samuel Bowden, Jr.
  • Patent number: 11858922
    Abstract: The present invention relates to compounds of formula (I), and pharmaceutically acceptable salts, solvates and prodrugs thereof: wherein Q is selected from O, S and Se; J is S or Se; W1 and W2, when present, are independently selected from N and C; R1 and R2 are independently selected from the group consisting of hydrogen, C1-C12 alkyl, C2-C12 alkenyl, C2-C12 alkynyl, aryl, heterocyclyl, heteroaryl, cycloalkyl, cycloalkenyl, amino, amido, alkylthio, acyl, arylalkyl and acylamido, all of which may be optionally substituted; and wherein at least one of W1 and W2 is present and is a nitrogen atom and when R1 or R2 are cyclic then the respective W1 or W2 may form part of the ring structure. The present invention also relates to pharmaceutical compositions including such compounds, to methods of treatment using such compounds, in particular in relation to NLRP3 inflammasome mediated disorders, and to associated diagnostic uses.
    Type: Grant
    Filed: February 16, 2017
    Date of Patent: January 2, 2024
    Assignees: THE UNIVERSITY OF QUEENSLAND, THE PROVOST, FELLOWS, FOUNDATION SCHOLARS, AND THE OTHER MEMBERS OF BOARD, OF THE COLLEGE OF THE HOLY AND UNDIVIDED TRINITY OF QUEEN ELIZABETH NEAR DUBLIN
    Inventors: Luke O'Neill, Rebecca Coll, Matthew Cooper, Avril Robertson, Kate Schroder, Angus Murray Macleod, David John Miller
  • Patent number: 11845715
    Abstract: The present invention provides for certain sulfonyl ureas and related compounds which have advantageous properties and show useful activity in the inhibition of activation of the NLRP3 inflammasome. Such compounds are useful in the treatment of a wide range of disorders in which the inflammation process, or more specifically the NLRP3 inflammasome, have been implicated as being a key factor.
    Type: Grant
    Filed: August 18, 2021
    Date of Patent: December 19, 2023
    Assignees: THE UNIVERSITY OF QUEENSLAND, THE PROVOST, FELLOWS, FOUNDATION SCHOLARS, AND THE OTHER MEMBERS OF BOARD, OF THE COLLEGE OF THE HOLY AND UNDIVIDED TRINITY OF QUEEN ELIZABETH NEAR DUBLIN
    Inventors: Luke O'Neill, Rebecca Coll, Matthew Cooper, Avril Robertson, Kate Schroder
  • Patent number: 11840543
    Abstract: The present invention relates to compounds of formula (I): wherein Q is O or S; R1 is a cyclic group substituted with at least one group X, wherein R1 may optionally be further substituted; X is any group comprising a carbonyl group; and R2 is a cyclic group substituted at the ?-position, wherein R2 may optionally be further substituted. The present invention further relates to salts, solvates and prodrugs of such compounds, to pharmaceutical compositions comprising such compounds, and to the use of such compounds in the treatment and prevention of medical disorders and diseases, most especially by the dual action of NLRP3 inhibition and the stimulation of insulin secretion.
    Type: Grant
    Filed: May 24, 2017
    Date of Patent: December 12, 2023
    Assignees: THE UNIVERSITY OF QUEENSLAND, THE PROVOST, FELLOWS, FOUNDATION SCHOLARS, AND THE OTHER MEMBERS OF BOARD, OF THE COLLEGE OF THE HOLY AND UNDIVIDED TRINITY OF QUEEN ELIZABETH NEAR DUBLIN
    Inventors: Luke O'Neill, Rebecca Coll, Matthew Cooper, Avril Robertson, Kate Schroder, Angus Murray MacLeod, David John Miller
  • Patent number: 11834433
    Abstract: The present invention relates to compounds of formula (I): comprising a 5-membered nitrogen-containing heteroaryl ring A, wherein the heteroaryl ring A is substituted with at least one group containing an oxygen atom, and wherein said oxygen atom is attached to the heteroaryl ring A via at least two other atoms. The present invention further relates to salts, solvates and prodrugs of such compounds, to pharmaceutical compositions comprising such compounds, and to the use of such compounds in the treatment and prevention of medical disorders and diseases, most especially by the inhibition of NLRP3.
    Type: Grant
    Filed: March 1, 2019
    Date of Patent: December 5, 2023
    Assignee: INFLAZOME LIMITED
    Inventors: David Miller, Jimmy Van Wiltenburg, Matthew Cooper
  • Publication number: 20230360659
    Abstract: A method for representing a second presentation of audio channels or objects as a data stream, the method comprising the steps of: (a) providing a set of base signals, the base signals representing a first presentation of the audio channels or objects; (b) providing a set of transformation parameters, the transformation parameters intended to transform the first presentation into the second presentation; the transformation parameters further being specified for at least two frequency bands and including a set of multi-tap convolution matrix parameters for at least one of the frequency bands.
    Type: Application
    Filed: July 13, 2023
    Publication date: November 9, 2023
    Applicants: Dolby Laboratories Licensing Corporation, Dolby International AB
    Inventors: Dirk Jeroen Breebaart, David Matthew Cooper, Leif Jonas Samuelsson
  • Publication number: 20230345192
    Abstract: Methods for dialogue enhancing audio content, comprising providing a first audio signal presentation of the audio components, providing a second audio signal presentation, receiving a set of dialogue estimation parameters configured to enable estimation of dialogue components from the first audio signal presentation, applying said set of dialogue estimation parameters to said first audio signal presentation, to form a dialogue presentation of the dialogue components; and combining the dialogue presentation with said second audio signal presentation to form a dialogue enhanced audio signal presentation for reproduction on the second audio reproduction system, wherein at least one of said first and second audio signal presentation is a binaural audio signal presentation.
    Type: Application
    Filed: April 28, 2023
    Publication date: October 26, 2023
    Applicants: Dolby Laboratories Licensing Corporation, DOLBY INTERNATIONAL AB
    Inventors: Leif Jonas Samuelsson, Dirk Jeroen Breebaart, David Matthew Cooper, Jeroen Koppens
  • Patent number: D1023679
    Type: Grant
    Filed: December 16, 2021
    Date of Patent: April 23, 2024
    Inventors: Lena Ripley, Matthew Cooper, Nick Hansen
  • Patent number: D1024063
    Type: Grant
    Filed: November 2, 2021
    Date of Patent: April 23, 2024
    Assignee: LOGITECH EUROPE S.A.
    Inventors: James Leigh Toggweiler, Steven Ryutaro Takayama, Anthony Cooper Mattana, Matthew Fumio Yamamoto, Adam Kirk Bennett, Aron Michael Rosenberg